{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T04:10:05Z","timestamp":1784175005627,"version":"3.55.0"},"reference-count":135,"publisher":"Tech Science Press","issue":"11","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["OR"],"published-print":{"date-parts":[[2025]]},"DOI":"10.32604\/or.2025.067445","type":"journal-article","created":{"date-parts":[[2025,7,10]],"date-time":"2025-07-10T09:20:01Z","timestamp":1752139201000},"page":"3347-3373","source":"Crossref","is-referenced-by-count":3,"title":["Universal CAR-T Cell Therapy for Cancer Treatment: Advances and Challenges"],"prefix":"10.32604","volume":"33","author":[{"given":"Jianan","family":"Lei","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhuona","family":"Ni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruidi","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"17807","published-online":{"date-parts":[[2025]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1007\/s12032-023-02146-y","article-title":"Revolutionizing cancer treatment: a comprehensive review of CAR-T cell therapy","volume":"40","author":"Dabas","year":"2023","journal-title":"Med Oncol"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"10024","DOI":"10.1073\/pnas.86.24.10024","article-title":"Expression of immunoglobulin-T-cell receptor chimeric molecules as functional receptors with antibody-type specificity","volume":"86","author":"Gross","year":"1989","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1038\/s41596-020-00467-0","article-title":"Comparative analysis of assays to measure CAR T-cell-mediated cytotoxicity","volume":"16","author":"Kiesgen","year":"2021","journal-title":"Nat Protoc"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"1165576","DOI":"10.3389\/fimmu.2023.1165576","volume":"14","author":"Qin","year":"2023","journal-title":"Front Immunol"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1158\/2159-8290.CD-18-0297","article-title":"CARs versus BiTEs: a comparison between T cell-redirection strategies for cancer treatment","volume":"8","author":"Slaney","year":"2018","journal-title":"Cancer Discov"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1038\/s41551-018-0235-9","article-title":"Programming CAR-T cells to kill cancer","volume":"2","author":"Labanieh","year":"2018","journal-title":"Nat Biomed Eng"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1038\/s41591-018-0201-9","article-title":"Induction of resistance to chimeric antigen receptor T cell therapy by transduction of a single leukemic B cell","volume":"24","author":"Ruella","year":"2018","journal-title":"Nat Med"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1038\/s41573-019-0051-2","article-title":"\u2018Off-the-shelf\u2019 allogeneic CAR T cells: development and challenges","volume":"19","author":"Depil","year":"2020","journal-title":"Nat Rev Drug Discov"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1038\/s41571-023-00754-1","article-title":"Long-term outcomes following CAR T cell therapy: what we know so far","volume":"20","author":"Cappell","year":"2023","journal-title":"Nat Rev Clin Oncol"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"2548","DOI":"10.7150\/ijbs.34213","article-title":"Current progress in CAR-T cell therapy for solid tumors","volume":"15","author":"Ma","year":"2019","journal-title":"Int J Biol Sci"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1146\/annurev-med-062315-120245","article-title":"CAR T cell therapy for solid tumors","volume":"68","author":"Newick","year":"2017","journal-title":"Annu Rev Med"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"896685","DOI":"10.3389\/fimmu.2022.896685","article-title":"Clinical investigations of CAR-T cell therapy for solid tumors","volume":"13","author":"Chen","year":"2022","journal-title":"Front Immunol"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1080\/14712598.2021.1843628","article-title":"Mesothelin-targeted CAR-T cell therapy for solid tumors","volume":"21","author":"Klampatsa","year":"2021","journal-title":"Expert Opin Biol Ther"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1007\/s00262-022-03238-w","article-title":"Anti-mesothelin CAR-T immunotherapy in patients with ovarian cancer","volume":"72","author":"Chen","year":"2023","journal-title":"Cancer Immunol Immunother"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"e552","DOI":"10.1002\/mco2.552","article-title":"Deleting SUV39H1 in CAR-T cells epigenetically enhances the antitumor function","volume":"5","author":"Wang","year":"2024","journal-title":"MedComm"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1038\/s41423-024-01207-0","article-title":"CAR-T and CAR-NK as cellular cancer immunotherapy for solid tumors","volume":"21","author":"Peng","year":"2024","journal-title":"Cell Mol Immunol"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"15688","DOI":"10.3390\/ijms242115688","article-title":"CAR-T cell therapy: from the shop to cancer therapy","volume":"24","author":"Uscanga-Palomeque","year":"2023","journal-title":"Int J Mol Sci"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1038\/s41573-021-00189-2","article-title":"Navigating CAR-T cells through the solid-tumour microenvironment","volume":"20","author":"Hou","year":"2021","journal-title":"Nat Rev Drug Discov"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1016\/j.cell.2017.12.002","article-title":"CD19 CAR T cells","volume":"171","author":"Sadelain","year":"2017","journal-title":"Cell"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1002\/ajh.25418","article-title":"An introduction to chimeric antigen receptor (CAR) T-cell immunotherapy for human cancer","volume":"94","author":"Feins","year":"2019","journal-title":"Am J Hematol"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"8996","DOI":"10.3390\/ijms22168996","article-title":"CAR T-cell therapy in hematological malignancies","volume":"22","author":"Haslauer","year":"2021","journal-title":"Int J Mol Sci"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1038\/s41571-022-00704-3","article-title":"Overcoming on-target, off-tumour toxicity of CAR T cell therapy for solid tumours","volume":"20","author":"Flugel","year":"2023","journal-title":"Nat Rev Clin Oncol"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1038\/s41571-021-00476-2","article-title":"Immunogenicity of CAR T cells in cancer therapy","volume":"18","author":"Wagner","year":"2021","journal-title":"Nat Rev Clin Oncol"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1038\/nrclinonc.2016.36","article-title":"Driving CAR T-cells forward","volume":"13","author":"Jackson","year":"2016","journal-title":"Nat Rev Clin Oncol"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1016\/j.ccell.2020.07.005","article-title":"Engineering CAR-T cells for next-generation cancer therapy","volume":"38","author":"Hong","year":"2020","journal-title":"Cancer Cell"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"e1363139","DOI":"10.1080\/2162402X.2017.1363139","article-title":"Trial watch: adoptively transferred cells for anticancer immunotherapy","volume":"6","author":"Fournier","year":"2017","journal-title":"Oncoimmunology"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1093\/oncolo\/oyac054","article-title":"FDA approval summary: axicabtagene ciloleucel for relapsed or refractory follicular lymphoma","volume":"27","author":"Bouchkouj","year":"2022","journal-title":"Oncologist"},{"key":"ref28","unstructured":"Administration USFaD. FDA approves brexucabtagene autoleucel for relapsed or refractory B-cell precursor acute lymphoblastic leukemia. [Internet] [cited 2025 Jun 1]. Available from: https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-brexucabtagene-autoleucel-relapsed-or-refractory-b-cell-precursor-acute-lymphoblastic."},{"key":"ref29","unstructured":"Administration USFaD. FDA approves lisocabtagene maraleucel for relapsed or refractory mantle cell lymphoma. [Internet] [cited 2025 Jun 1]. Available from: https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-lisocabtagene-maraleucel-relapsed-or-refractory-mantle-cell-lymphoma."},{"key":"ref30","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.1158\/1078-0432.CCR-21-3803","article-title":"FDA approval summary: idecabtagene vicleucel for relapsed or refractory multiple myeloma","volume":"28","author":"Sharma","year":"2022","journal-title":"Clin Cancer Res"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"2865","DOI":"10.1158\/1078-0432.CCR-24-0378","article-title":"FDA approval summary: ciltacabtagene autoleucel for relapsed or refractory multiple myeloma","volume":"30","author":"Natrajan","year":"2024","journal-title":"Clin Cancer Res"},{"key":"ref32","unstructured":"Administration USFaD. FDA approves obecabtagene autoleucel for adults with relapsed or re-fractory B-cell precursor acute lymphoblastic leukemia. [Internet] [cited 2025 Jun 1]. Available from: https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-obecabtagene-autoleucel-adults-relapsed-or-refractory-b-cell-precursor-acute."},{"key":"ref33","doi-asserted-by":"crossref","first-page":"876339","DOI":"10.3389\/fimmu.2022.876339","article-title":"Impact of manufacturing procedures on CAR T cell functionality","volume":"13","author":"Watanabe","year":"2022","journal-title":"Front Immunol"},{"key":"ref34","doi-asserted-by":"crossref","first-page":"1101495","DOI":"10.3389\/fimmu.2023.1101495","article-title":"CAR-T cell therapy in multiple myeloma: current limitations and potential strategies","volume":"14","author":"Zhang","year":"2023","journal-title":"Front Immunol"},{"key":"ref35","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1186\/s40364-022-00434-9","article-title":"Strategies to enhance CAR-T persistence","volume":"10","author":"Liu","year":"2022","journal-title":"Biomark Res"},{"key":"ref36","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1016\/j.apsb.2018.03.001","article-title":"The application of CAR-T cell therapy in hematological malignancies: advantages and challenges","volume":"8","author":"Zhao","year":"2018","journal-title":"Acta Pharm Sin B"},{"key":"ref37","doi-asserted-by":"crossref","first-page":"1188049","DOI":"10.3389\/fimmu.2023.1188049","article-title":"From bench to bedside: the history and progress of CAR T cell therapy","volume":"14","author":"Mitra","year":"2023","journal-title":"Front Immunol"},{"key":"ref38","doi-asserted-by":"crossref","first-page":"1034707","DOI":"10.3389\/fimmu.2022.1034707","article-title":"Next generations of CAR-T cells\u2014new therapeutic opportunities in hematology?","volume":"13","author":"Tomasik","year":"2022","journal-title":"Front Immunol"},{"key":"ref39","doi-asserted-by":"crossref","first-page":"1924","DOI":"10.1001\/jama.2024.19462","article-title":"CAR T cells and T-cell therapies for cancer","volume":"332","author":"Brudno","year":"2024","journal-title":"JAMA"},{"key":"ref40","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1186\/s12943-023-01723-z","article-title":"CAR-cell therapy in the era of solid tumor treatment: current challenges and emerging therapeutic advances","volume":"22","author":"Maalej","year":"2023","journal-title":"Mol Cancer"},{"key":"ref41","doi-asserted-by":"crossref","first-page":"5019","DOI":"10.1002\/cam4.4064","article-title":"Current progress in chimeric antigen receptor T cell therapy for glioblastoma multiforme","volume":"10","author":"Marei","year":"2021","journal-title":"Cancer Med"},{"key":"ref42","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1038\/s41586-024-08171-9","volume":"637","author":"Monje","year":"2025","journal-title":"Nature"},{"key":"ref43","doi-asserted-by":"crossref","first-page":"927153","DOI":"10.3389\/fimmu.2022.927153","article-title":"CAR-T cell therapy in hematological malignancies: current opportunities and challenges","volume":"13","author":"Zhang","year":"2022","journal-title":"Front Immunol"},{"key":"ref44","doi-asserted-by":"crossref","first-page":"100826","DOI":"10.1016\/j.currproblcancer.2021.100826","article-title":"CAR T-cell therapy for B-cell lymphoma","volume":"46","author":"Denlinger","year":"2022","journal-title":"Curr Probl Cancer"},{"key":"ref45","doi-asserted-by":"crossref","first-page":"1288383","DOI":"10.3389\/fonc.2023.1288383","article-title":"CAR-T treatment for cancer: prospects and challenges","volume":"13","author":"Chen","year":"2023","journal-title":"Front Oncol"},{"key":"ref46","doi-asserted-by":"crossref","first-page":"12317","DOI":"10.3390\/ijms241512317","article-title":"CRISPR\/Cas9: a powerful strategy to improve CAR-T cell persistence","volume":"24","author":"Wei","year":"2023","journal-title":"Int J Mol Sci"},{"key":"ref47","doi-asserted-by":"crossref","first-page":"744823","DOI":"10.3389\/fimmu.2021.744823","article-title":"Advances in universal CAR-T cell therapy","volume":"12","author":"Lin","year":"2021","journal-title":"Front Immunol"},{"key":"ref48","doi-asserted-by":"crossref","first-page":"5186","DOI":"10.1111\/febs.13110","article-title":"Genome modification by CRISPR\/Cas9","volume":"281","author":"Ma","year":"2014","journal-title":"FEBS J"},{"key":"ref49","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1186\/s12943-022-01518-8","article-title":"Current applications and future perspective of CRISPR\/Cas9 gene editing in cancer","volume":"21","author":"Wang","year":"2022","journal-title":"Mol Cancer"},{"key":"ref50","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1007\/s00005-016-0427-5","article-title":"CRISPR\/Cas9 immune system as a tool for genome engineering","volume":"65","author":"Hryhorowicz","year":"2017","journal-title":"Arch Immunol Ther Exp"},{"key":"ref51","doi-asserted-by":"crossref","first-page":"1143157","DOI":"10.3389\/fbioe.2023.1143157","article-title":"Off-target effects in CRISPR\/Cas9 gene editing","volume":"11","author":"Guo","year":"2023","journal-title":"Front Bioeng Biotechnol"},{"key":"ref52","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.gene.2017.09.010","article-title":"CRISPR knock out CTLA-4 enhances the anti-tumor activity of cytotoxic T lymphocytes","volume":"636","author":"Shi","year":"2017","journal-title":"Gene"},{"key":"ref53","doi-asserted-by":"crossref","first-page":"1935","DOI":"10.3390\/cancers13081935","article-title":"CD80 expression on tumor cells alters tumor microenvironment and efficacy of cancer immunotherapy by CTLA-4 blockade","volume":"13","author":"Vackova","year":"2021","journal-title":"Cancers"},{"key":"ref54","doi-asserted-by":"crossref","first-page":"848327","DOI":"10.3389\/fimmu.2022.848327","article-title":"Effect of CRISPR\/Cas9-edited PD-1\/PD-L1 on tumor immunity and immunotherapy","volume":"13","author":"Xu","year":"2022","journal-title":"Front Immunol"},{"key":"ref55","doi-asserted-by":"crossref","first-page":"eaba7365","DOI":"10.1126\/science.aba7365","article-title":"CRISPR-engineered T cells in patients with refractory cancer","volume":"367","author":"Stadtmauer","year":"2020","journal-title":"Science"},{"key":"ref56","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1186\/s13046-025-03273-2","article-title":"LLT1 overexpression renders allogeneic-NK resistance and facilitates the generation of enhanced universal CAR-T cells","volume":"44","author":"Zhu","year":"2025","journal-title":"J Exp Clin Cancer Res"},{"key":"ref57","doi-asserted-by":"crossref","first-page":"3915","DOI":"10.1016\/j.ymthe.2024.08.018","article-title":"TALEN-edited allogeneic inducible dual CAR T cells enable effective targeting of solid tumors while mitigating off-tumor toxicity","volume":"32","author":"Dharani","year":"2024","journal-title":"Mol Ther"},{"key":"ref58","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1534\/genetics.111.131433","article-title":"Genome engineering with zinc-finger nucleases","volume":"188","author":"Carroll","year":"2011","journal-title":"Genetics"},{"key":"ref59","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1111\/j.1365-3083.2012.02680.x","article-title":"Alloreactivity: an old puzzle revisited","volume":"75","author":"Nagy","year":"2012","journal-title":"Scand J Immunol"},{"key":"ref60","doi-asserted-by":"crossref","first-page":"2717","DOI":"10.3389\/fimmu.2019.02717","article-title":"Universal ready-to-use immunotherapeutic approach for the treatment of cancer: expanded and activated polyclonal \u03b3\u03b4 memory T cells","volume":"10","author":"Polito","year":"2019","journal-title":"Front Immunol"},{"key":"ref61","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1186\/s13045-020-00998-9","article-title":"Chimeric antigen receptor-engineered natural killer cells for cancer immunotherapy","volume":"13","author":"Yilmaz","year":"2020","journal-title":"J Hematol Oncol"},{"key":"ref62","doi-asserted-by":"crossref","first-page":"3061","DOI":"10.3389\/fimmu.2018.03061","article-title":"Regulation of GVHD and GVL activity via PD-L1 interaction with PD-1 and CD80","volume":"9","author":"Cassady","year":"2018","journal-title":"Front Immunol"},{"key":"ref63","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1186\/s12943-022-01559-z","article-title":"Engineering the next-generation of CAR T-cells with CRISPR-Cas9 gene editing","volume":"21","author":"Dimitri","year":"2022","journal-title":"Mol Cancer"},{"key":"ref64","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1007\/s00262-023-03586-1","article-title":"Allogeneic CAR-T cells with of HLA-A\/B and TRAC disruption exhibit promising antitumor capacity against B cell malignancies","volume":"73","author":"Chen","year":"2024","journal-title":"Cancer Immunol Immunother"},{"key":"ref65","doi-asserted-by":"crossref","first-page":"1531294","DOI":"10.3389\/fimmu.2024.1531294","article-title":"A self-activated and protective module enhances the preclinical performance of allogeneic anti-CD70 CAR-T cells","volume":"15","author":"Zhang","year":"2025","journal-title":"Front Immunol"},{"key":"ref66","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1186\/s40425-019-0806-7","article-title":"CRISPR-Cas9 disruption of PD-1 enhances activity of universal EGFRvIII CAR T cells in a preclinical model of human glioblastoma","volume":"7","author":"Choi","year":"2019","journal-title":"J Immunother Cancer"},{"key":"ref67","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1038\/s41587-024-02226-y","article-title":"Generation of allogeneic CAR-NKT cells from hematopoietic stem and progenitor cells using a clinically guided culture method","volume":"43","author":"Li","year":"2025","journal-title":"Nat Biotechnol"},{"key":"ref68","doi-asserted-by":"crossref","first-page":"S4","DOI":"10.1634\/theoncologist.2020-0570","article-title":"First allogeneic CAR T-Cell therapy impresses in relapsed\/refractory lymphoma","volume":"25","year":"2020","journal-title":"Oncologist"},{"key":"ref69","doi-asserted-by":"crossref","first-page":"4620","DOI":"10.1182\/blood-2022-158231","article-title":"Universal updated phase 1 data highlights role of allogeneic anti-BCMA ALLO-715 therapy for relapsed\/refractory multiple myeloma","volume":"140","author":"Mailankody","year":"2022","journal-title":"Blood"},{"key":"ref70","doi-asserted-by":"crossref","first-page":"2817","DOI":"10.1182\/blood-2021-147738","article-title":"Immunicy-1: targeting BCMA with cyad-211 to establish proof of concept of an shRNA-based allogeneic CAR T cell therapy platform","volume":"138","author":"Al-Homsi","year":"2021","journal-title":"Blood"},{"key":"ref71","doi-asserted-by":"crossref","first-page":"10303","DOI":"10.1182\/blood-2022-166432","article-title":"CTX110 allogeneic CRISPR-Cas9-engineered CAR T cells in patients (pts) with relapsed or refractory (R\/R) large B-cell lymphoma (LBCL): results from the phase 1 dose escalation carbon study","volume":"140","author":"McGuirk","year":"2022","journal-title":"Blood"},{"key":"ref72","doi-asserted-by":"crossref","first-page":"4577","DOI":"10.1182\/blood-2022-167194","article-title":"Interim phase I clinical data of FT819-101, a study of the first-ever, off-the-shelf, iPSC-derived TCR-less CD19 CAR T-cell therapy for patients with relapsed\/refractory B-cell malignancies","volume":"140","author":"Mehta","year":"2022","journal-title":"Blood"},{"key":"ref73","doi-asserted-by":"crossref","first-page":"3479","DOI":"10.1182\/blood-2023-182430","article-title":"Early safety results of P-BCMA-ALLO1, a fully allogeneic chimeric antigen receptor T-cell (CAR-T), in patients with relapsed\/refractory multiple myeloma (RRMM)","volume":"142","author":"Dholaria","year":"2023","journal-title":"Blood"},{"key":"ref74","doi-asserted-by":"crossref","first-page":"2110","DOI":"10.1182\/blood-2023-186570","article-title":"Preliminary results of nathali-01: a first-in-human phase I\/IIa study of UCART20 \u00d7 22, a dual allogeneic CAR-T cell product targeting CD20 and CD22, in relapsed or refractory (R\/R) non-Hodgkin lymphoma (NHL)","volume":"142","author":"Abramson","year":"2023","journal-title":"Blood"},{"key":"ref75","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/S1470-2045(24)00508-4","article-title":"Safety and activity of CTX130, a CD70-targeted allogeneic CRISPR-Cas9-engineered CAR T-cell therapy, in patients with relapsed or refractory T-cell malignancies (COBALT-LYM): a single-arm, open-label, phase 1, dose-escalation study","volume":"26","author":"Iyer","year":"2025","journal-title":"Lancet Oncol"},{"key":"ref76","doi-asserted-by":"crossref","first-page":"CT196","DOI":"10.1158\/1538-7445.AM2022-CT196","article-title":"Abstract CT196: early results of a safety and efficacy study of allogeneic TruUCAR\u2122 GC502 in patients with relapsed\/refractory B-cell acute lymphoblastic leukemia (r\/r B-ALL)","volume":"82","author":"Li","year":"2022","journal-title":"Cancer Res"},{"key":"ref77","doi-asserted-by":"crossref","first-page":"4847","DOI":"10.1182\/blood-2023-187252","article-title":"Updated results of the phase I BALLI-01 trial of UCART22 process 2 (P2), an anti-CD22 allogeneic CAR-T cell product manufactured by cellectis biologics, in patients with relapsed or refractory (R\/R) CD22+ B-cell acute lymphoblastic leukemia (B-ALL)","volume":"142","author":"Jain","year":"2023","journal-title":"Blood"},{"key":"ref78","doi-asserted-by":"crossref","first-page":"2111","DOI":"10.1182\/blood-2023-189052","article-title":"Intracellular retention of tcr\u03b1\u03b2\/CD3 to generate novel allogeneic CAR-T cells (ThisCART19A) with enhanced antitumor potency for treating B-ALL","volume":"142","author":"Hu","year":"2023","journal-title":"Blood"},{"key":"ref79","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1182\/blood-2018-99-111356","article-title":"Preliminary data on safety, cellular kinetics and anti-leukemic activity of UCART19, an allogeneic anti-CD19 CAR T-cell product, in a pool of adult and pediatric patients with high-risk CD19+ relapsed\/refractory B-cell acute lymphoblastic leukemia","volume":"132","author":"Benjamin","year":"2018","journal-title":"Blood"},{"key":"ref80","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1182\/blood-2021-153166","article-title":"Preliminary safety and efficacy of PBCAR0191, an allogeneic \u2018off-the-shelf\u2019 CD19-directed CAR-T for patients with relapsed\/refractory (R\/R) CD19+ B-ALL","volume":"138","author":"Jain","year":"2021","journal-title":"Blood"},{"key":"ref81","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1182\/blood-2023-178723","article-title":"Phase 1\/2 dose-escalation\/dose-expansion study of anti-CD7 allogeneic CAR-T cells (WU-CART-007) in relapsed or refractory (R\/R) T-cell acute lymphoblastic leukemia\/lymphoblastic lymphoma (T-ALL\/LBL)","volume":"142","author":"Ghobadi","year":"2023","journal-title":"Blood"},{"key":"ref82","doi-asserted-by":"crossref","first-page":"eabq3010","DOI":"10.1126\/scitranslmed.abq3010","article-title":"Phase 1 clinical trial of CRISPR-engineered CAR19 universal T cells for treatment of children with refractory B cell leukemia","volume":"14","author":"Ottaviano","year":"2022","journal-title":"Sci Transl Med"},{"key":"ref83","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1182\/blood-2020-142262","article-title":"The safety and efficacy of a CRISPR\/Cas9-engineered universal CAR-T cell product (CTA101) in patients with relapsed\/refractory B-cell acute lymphoblastic leukemia","volume":"136","author":"Hu","year":"2020","journal-title":"Blood"},{"key":"ref84","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1038\/s41422-022-00721-y","article-title":"Genetically modified CD7-targeting allogeneic CAR-T cell therapy with enhanced efficacy for relapsed\/refractory CD7-positive hematological malignancies: a phase I clinical study","volume":"32","author":"Hu","year":"2022","journal-title":"Cell Res"},{"key":"ref85","doi-asserted-by":"crossref","first-page":"6021","DOI":"10.1172\/JCI138473","article-title":"Sleeping beauty-engineered CAR T cells achieve antileukemic activity without severe toxicities","volume":"130","author":"Magnani","year":"2020","journal-title":"J Clin Invest"},{"key":"ref86","doi-asserted-by":"crossref","first-page":"6852","DOI":"10.1182\/blood-2023-179441","article-title":"Phase 1 study of SC291, a hypoimmune, allogeneic CD19-directed CAR T cell therapy for relapsed\/refractory B-cell malignancies (ARDENT)\u2014initial clinical data","volume":"142","author":"Neelapu","year":"2023","journal-title":"Blood"},{"key":"ref87","doi-asserted-by":"crossref","first-page":"3465","DOI":"10.1182\/blood-2023-177867","article-title":"Updated results from a phase I dose escalation study of the rapidly-switchable universal CAR-T therapy UniCAR-T-CD123 in relapsed\/refractory AML","volume":"142","author":"Wermke","year":"2023","journal-title":"Blood"},{"key":"ref88","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1182\/blood-2023-179667","article-title":"CD33 CAR T-cells (CD33CART) for children and young adults with relapsed\/refractory AML: dose-escalation results from a phase I\/II multicenter trial","volume":"142","author":"Shah","year":"2023","journal-title":"Blood"},{"key":"ref89","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1056\/NEJMoa2300709","article-title":"Base-edited CAR7 T cells for relapsed T-cell acute lymphoblastic leukemia","volume":"389","author":"Chiesa","year":"2023","journal-title":"N Engl J Med"},{"key":"ref90","doi-asserted-by":"crossref","first-page":"1491341","DOI":"10.3389\/fimmu.2024.1491341","article-title":"Utilization of donor CLL-1 CAR-T cells for the treatment of relapsed of acute myeloid leukemia following allogeneic hematopoietic stem cell transplantation","volume":"15","author":"Zhang","year":"2025","journal-title":"Front Immunol"},{"key":"ref91","doi-asserted-by":"crossref","first-page":"1644","DOI":"10.1182\/bloodadvances.2024015157","article-title":"Allogeneic off-the-shelf CAR T-cell therapy for relapsed or refractory B-cell malignancies","volume":"9","author":"Shahid","year":"2025","journal-title":"Blood Adv"},{"key":"ref92","doi-asserted-by":"crossref","first-page":"102377","DOI":"10.1016\/j.eclinm.2023.102377","article-title":"Donor-derived Anti-CD19 CAR T cells GC007g for relapsed or refractory B-cell acute lymphoblastic leukemia after allogeneic HSCT: a phase 1 trial","volume":"67","author":"Luo","year":"2023","journal-title":"eClinicalMedicine"},{"key":"ref93","doi-asserted-by":"crossref","first-page":"4617","DOI":"10.1182\/blood-2022-157400","article-title":"A phase 1 study of ADI-001: anti-CD20 CAR-engineered allogeneic gamma Delta1 (\u03b3\u03b4) T cells in adults with B-cell malignancies","volume":"140","author":"Neelapu","year":"2022","journal-title":"Blood"},{"key":"ref94","doi-asserted-by":"crossref","first-page":"3476","DOI":"10.1182\/blood-2023-180753","article-title":"Long term follow-up after treatment with allogeneic off-the-shelf CAR T cell therapy for relapsed or refractory B-cell malignancies","volume":"142","author":"Shahid","year":"2023","journal-title":"Blood"},{"key":"ref95","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1182\/blood-2022-160244","article-title":"CD30.CAR-modified epstein-barr virus-specific T cells (CD30.CAR EBVSTs) provide a safe and effective off-the-shelf therapy for patients with CD30-positive lymphoma","volume":"140","author":"Quach","year":"2022","journal-title":"Blood"},{"key":"ref96","doi-asserted-by":"crossref","first-page":"2965","DOI":"10.1182\/blood-2013-06-506741","article-title":"Infusion of donor-derived CD19-redirected virus-specific T cells for B-cell malignancies relapsed after allogeneic stem cell transplant: a phase 1 study","volume":"122","author":"Cruz","year":"2013","journal-title":"Blood"},{"key":"ref97","doi-asserted-by":"crossref","first-page":"102516","DOI":"10.1016\/j.eclinm.2024.102516","article-title":"CD19-CAR-DNT cells (RJMty19) in patients with relapsed or refractory large B-cell lymphoma: a phase 1, first-in-human study","volume":"70","author":"Xiao","year":"2024","journal-title":"eClinicalMedicine"},{"key":"ref98","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1200\/JCO.2021.39.3_suppl.74","article-title":"Updated data from alloSHRINK phase I first-in-human study evaluating CYAD-101, an innovative non-gene edited allogeneic CAR-T in mCRC","volume":"39","author":"Prenen","year":"2021","journal-title":"J Clin Oncol"},{"key":"ref99","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1038\/s41591-024-03449-x","article-title":"Donor-derived GD2-specific CAR T cells in relapsed or refractory neuroblastoma","volume":"31","author":"Quintarelli","year":"2025","journal-title":"Nat Med"},{"key":"ref100","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1158\/2159-8290.CD-24-0102","article-title":"CD70-targeted allogeneic CAR T-cell therapy for advanced clear cell renal cell carcinoma","volume":"14","author":"Pal","year":"2024","journal-title":"Cancer Discov"},{"key":"ref101","doi-asserted-by":"crossref","first-page":"e008417","DOI":"10.1136\/jitc-2023-008417","article-title":"Stealth transgenes enable CAR-T cells to evade host immune responses","volume":"12","author":"Grauwet","year":"2024","journal-title":"J Immunother Cancer"},{"key":"ref102","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1089\/hum.2023.029","article-title":"Universal anti-CD7 CAR-T cells targeting T-ALL and functional analysis of CD7 antigen on T\/CAR-T cells","volume":"34","author":"Xie","year":"2023","journal-title":"Hum Gene Ther"},{"key":"ref103","doi-asserted-by":"crossref","first-page":"1011858","DOI":"10.3389\/fimmu.2022.1011858","article-title":"Efficacy and safety of universal (TCRKO) ARI-0001 CAR-T cells for the treatment of B-cell lymphoma","volume":"13","author":"Maldonado-P\u00e9rez","year":"2022","journal-title":"Front Immunol"},{"key":"ref104","doi-asserted-by":"crossref","first-page":"4920","DOI":"10.3390\/ijms23094920","article-title":"Targeting CD10 on B-cell leukemia using the universal CAR T-cell platform (UniCAR)","volume":"23","author":"Mitwasi","year":"2022","journal-title":"Int J Mol Sci"},{"key":"ref105","doi-asserted-by":"crossref","first-page":"718","DOI":"10.7150\/ijbs.14405","article-title":"New strategies for the treatment of solid tumors with CAR-T cells","volume":"12","author":"Zhang","year":"2016","journal-title":"Int J Biol Sci"},{"key":"ref106","doi-asserted-by":"crossref","first-page":"2214","DOI":"10.1016\/j.ymthe.2017.05.012","article-title":"CAR T cells administered in combination with lymphodepletion and PD-1 inhibition to patients with neuroblastoma","volume":"25","author":"Heczey","year":"2017","journal-title":"Mol Ther"},{"key":"ref107","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1038\/s41598-017-00462-8","article-title":"CRISPR\/Cas9-mediated PD-1 disruption enhances anti-tumor efficacy of human chimeric antigen receptor T cells","volume":"7","author":"Rupp","year":"2017","journal-title":"Sci Rep"},{"key":"ref108","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1007\/s00262-017-2007-x","article-title":"Current status of chimeric antigen receptor engineered T cell-based and immune checkpoint blockade-based cancer immunotherapies","volume":"66","author":"Hegde","year":"2017","journal-title":"Cancer Immunol Immunother"},{"key":"ref109","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1007\/s11427-016-5034-5","article-title":"Spotlight on chimeric antigen receptor engineered T cell research and clinical trials in China","volume":"59","author":"Luo","year":"2016","journal-title":"Sci China Life Sci"},{"key":"ref110","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1038\/s41587-023-02060-8","article-title":"IL-10-expressing CAR T cells resist dysfunction and mediate durable clearance of solid tumors and metastases","volume":"42","author":"Zhao","year":"2024","journal-title":"Nat Biotechnol"},{"key":"ref111","doi-asserted-by":"crossref","first-page":"155518","DOI":"10.1016\/j.prp.2024.155518","article-title":"Potential alternatives to \u03b1\u03b2-T cells to prevent graft-versus-host disease (GvHD) in allogeneic chimeric antigen receptor (CAR)-based cancer immunotherapy: a comprehensive review","volume":"262","author":"Tang","year":"2024","journal-title":"Pathol Res Pract"},{"key":"ref112","doi-asserted-by":"crossref","first-page":"1500177","DOI":"10.3389\/fimmu.2024.1500177","article-title":"GVHD after CAR T-cell therapy post allogeneic hematopoietic cell transplantation-successfully treated by extracorporeal photopheresis","volume":"15","author":"Farid","year":"2024","journal-title":"Front Immunol"},{"key":"ref113","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1182\/blood-2015-08-664250","article-title":"Murine allogeneic CD19 CAR T cells harbor potent antileukemic activity but have the potential to mediate lethal GVHD","volume":"127","author":"Jacoby","year":"2016","journal-title":"Blood"},{"key":"ref114","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1007\/s11864-023-01061-8","article-title":"Off-the-shelf allogeneic CAR cell therapy-neglected HvG effect","volume":"24","author":"An","year":"2023","journal-title":"Curr Treat Options Oncol"},{"key":"ref115","doi-asserted-by":"crossref","first-page":"101566","DOI":"10.1016\/j.beha.2024.101566","article-title":"Allogeneic \u201coff-the-shelf\u201d CAR T cells: challenges and advances","volume":"37","author":"Chen","year":"2024","journal-title":"Best Pract Res Clin Haematol"},{"key":"ref116","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","article-title":"ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells","volume":"25","author":"Lee","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"key":"ref117","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1016\/j.jaci.2020.07.025","article-title":"Cytokine release syndrome and neurotoxicity following CAR T-cell therapy for hematologic malignancies","volume":"146","author":"Freyer","year":"2020","journal-title":"J Allergy Clin Immunol"},{"key":"ref118","doi-asserted-by":"crossref","first-page":"3912","DOI":"10.3390\/cancers13153912","article-title":"Treatment-related adverse events of chimeric antigen receptor T-cell (CAR T) in clinical trials: a systematic review and meta-analysis","volume":"13","author":"Lei","year":"2021","journal-title":"Cancers"},{"key":"ref119","doi-asserted-by":"crossref","first-page":"102147","DOI":"10.1016\/j.tranon.2024.102147","article-title":"Universal CAR cell therapy: challenges and expanding applications","volume":"51","author":"Wu","year":"2025","journal-title":"Transl Oncol"},{"key":"ref120","doi-asserted-by":"crossref","first-page":"1052717","DOI":"10.3389\/fimmu.2022.1052717","article-title":"Simultaneous editing of TCR, HLA-I\/II and HLA-E resulted in enhanced universal CAR-T resistance to allo-rejection","volume":"13","author":"Li","year":"2022","journal-title":"Front Immunol"},{"key":"ref121","doi-asserted-by":"crossref","first-page":"663201","DOI":"10.3389\/fimmu.2021.663201","article-title":"Reactions related to CAR-T cell therapy","volume":"12","author":"Miao","year":"2021","journal-title":"Front Immunol"},{"key":"ref122","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1007\/s12185-024-03809-w","article-title":"CAR-T cell therapy in AML: recent progress and future perspectives","volume":"120","author":"Saito","year":"2024","journal-title":"Int J Hematol"},{"key":"ref123","first-page":"e10022","article-title":"T-cell therapy-mediated myocarditis secondary to cytokine release syndrome","volume":"12","author":"Afzal","year":"2020","journal-title":"Cureus"},{"key":"ref124","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.blre.2018.11.002","article-title":"Recent advances in CAR T-cell toxicity: mechanisms, manifestations and management","volume":"34","author":"Brudno","year":"2019","journal-title":"Blood Rev"},{"key":"ref125","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1016\/j.jaip.2021.10.037","article-title":"Hypogammaglobulinemia after chimeric antigen receptor (CAR) T-cell therapy: characteristics, management, and future directions","volume":"10","author":"Wat","year":"2022","journal-title":"J Allergy Clin Immunol Pract"},{"key":"ref126","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1007\/s00108-021-01042-9","article-title":"Economics and management of CAR T-cell therapy: status quo and future perspectives","volume":"62","author":"Kron","year":"2021","journal-title":"Internist"},{"key":"ref127","doi-asserted-by":"crossref","first-page":"2513","DOI":"10.1002\/eji.202049107","article-title":"Mutant B2M-HLA-E and B2M-HLA-G fusion proteins protects universal chimeric antigen receptor-modified T cells from allogeneic NK cell-mediated lysis","volume":"51","author":"Guo","year":"2021","journal-title":"Eur J Immunol"},{"key":"ref128","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1016\/j.hoc.2020.06.010","article-title":"Allogeneic transplantation and chimeric antigen receptor-engineered T-cell therapy for relapsed or refractory mantle cell lymphoma","volume":"34","author":"Gauthier","year":"2020","journal-title":"Hematol Oncol Clin North Am"},{"key":"ref129","doi-asserted-by":"crossref","first-page":"1365172","DOI":"10.3389\/fimmu.2024.1365172","article-title":"Universal CAR T cells targeted to HER2 with a biotin-trastuzumab soluble linker penetrate spheroids and large tumor xenografts that are inherently resistant to trastuzumab mediated ADCC","volume":"15","author":"Nagy","year":"2024","journal-title":"Front Immunol"},{"key":"ref130","doi-asserted-by":"crossref","first-page":"998","DOI":"10.3390\/cancers17060998","article-title":"CAR-\u03b3\u03b4 T cells targeting Claudin18.2 show superior cytotoxicity against solid tumor compared to traditional CAR-\u03b1\u03b2 T cells","volume":"17","author":"Zhao","year":"2025","journal-title":"Cancers"},{"key":"ref131","doi-asserted-by":"crossref","first-page":"121409","DOI":"10.1016\/j.lfs.2023.121409","article-title":"Explorations of CRISPR\/Cas9 for improving the long-term efficacy of universal CAR-T cells in tumor immunotherapy","volume":"316","author":"Naeem","year":"2023","journal-title":"Life Sci"},{"key":"ref132","doi-asserted-by":"crossref","first-page":"1172681","DOI":"10.3389\/fimmu.2023.1172681","article-title":"Stromal depletion by TALEN-edited universal hypoimmunogenic FAP-CAR T cells enables infiltration and anti-tumor cytotoxicity of tumor antigen-targeted CAR-T immunotherapy","volume":"14","author":"Das","year":"2023","journal-title":"Front Immunol"},{"key":"ref133","doi-asserted-by":"crossref","first-page":"4890","DOI":"10.1016\/j.cell.2024.06.027","article-title":"Allogeneic CD19-targeted CAR-T therapy in patients with severe myositis and systemic sclerosis","volume":"187","author":"Wang","year":"2024","journal-title":"Cell"},{"key":"ref134","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1038\/s41409-022-01866-5","volume":"58","author":"Palani","year":"2023","journal-title":"Bone Marrow Transplant"},{"key":"ref135","doi-asserted-by":"crossref","first-page":"101437","DOI":"10.1016\/j.omtm.2025.101437","article-title":"Efficient nonviral integration of large transgenes into human T cells using Cas9-CLIPT","volume":"33","author":"Tommasi","year":"2025","journal-title":"Mol Ther Methods Clin Dev"}],"container-title":["Oncology Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/cdn.techscience.cn\/files\/or\/2025\/TSP_OR-33-11\/OncolRes-33-11-67445\/OncolRes-33-67445.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,17]],"date-time":"2025-11-17T02:22:00Z","timestamp":1763346120000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.techscience.com\/or\/v33n11\/64071"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025]]},"references-count":135,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2025]]},"published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.32604\/or.2025.067445","relation":{},"ISSN":["1555-3906"],"issn-type":[{"value":"1555-3906","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025]]}}}